FDA approves amivantamab for head and neck cancer

• by Mouj Hijazi

• November 6, 2026

Misleading AI summaries may alter recall

Participants exposed to inaccurate postevent summaries were less likely to correctly remember key details from videos they had previously watched.

• by Andrea Surnit

• September 30, 2026

• 3 min

Low PET uptake may mask aortic sarcoma

Recurrent arterial embolization prompted surgery after imaging suggested thrombus, but definitive pathology revealed malignancy.

• by Andrea Surnit

• November 4, 2026

• 3 min

FDA clears targeted cholangiocarcinoma therapy

In the single-arm REFOCUS trial, 46% of patients responded to treatment, with a median response duration of 11.8 months.

• by Kathryn Wighton

• September 24, 2026

• 2 min